GlassScriptPhysician profile
Charles Raymond Graham
NPI 1720077290
$17,949.81
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,381 · 2020: $2,410 · 2021: $4,281 · 2022: $2,547 · 2023: $1,929 · 2024: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,832.85 | 2019-2024 | Farxiga, Tezspire, Airsupra |
| Novo Nordisk INC | $1,680.19 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,273.69 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $1,211.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $969.14 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $968.91 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $962.25 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $858.24 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $849.77 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $586.95 | 2019-2023 | Verquvo, Gardasil 9, Vaxneuvance |
| Amarin Pharma, INC. | $537.10 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $482.04 | 2020-2021 | |
| Esperion Therapeutics, INC. | $470.87 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $455.44 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $448.70 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.